Eintrag weiter verarbeiten
IC31®, a Two‐Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice
Gespeichert in:
| Zeitschriftentitel: | Scandinavian Journal of Immunology |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Scandinavian Journal of Immunology, 69, 2009, 3, S. 194-202 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| Zusammenfassung: | <jats:title>Abstract</jats:title><jats:p>IC31<jats:sup>®</jats:sup> is a novel adjuvant which combines the immunostimulatory effects of an 11‐mer antibacterial peptide (KLKL<jats:sub>5</jats:sub>KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll‐like receptor 9 agonist without containing cytosine phosphate guanine (CpG) motifs. The effects of IC31<jats:sup>®</jats:sup> on neonatal immune response to vaccination have not been reported. Neonatal mice were immunized once or twice with a <jats:italic>Streptococcus pneumoniae</jats:italic> serotype 1 polysaccharide conjugate containing Tetanus Toxoid (Pnc1‐TT) carrier protein, with or without IC31<jats:sup>®</jats:sup> or CpG‐ODN. IC31<jats:sup>®</jats:sup> significantly enhanced IgG1, IgG2a and IgG2b antibodies (Ab) to the serotype 1 polysaccharide. One dose of Pnc1‐TT and low dose IC31<jats:sup>®</jats:sup> elicited high Ab levels that protected the neonatal mice completely from bacteraemia and significantly reduced lung infection following i.n. challenge with serotype 1 pneumococcal strain. One‐sixth of an adult murine dose of IC31<jats:sup>®</jats:sup> was sufficient and optimal for induction of protective immunity in neonatal mice. Two doses of Pnc1‐TT with or without adjuvants protected the neonatal mice completely, but more rapid Ab response was observed when IC31<jats:sup>®</jats:sup> was given with the Pnc1‐TT. IC31<jats:sup>®</jats:sup> is a promising new adjuvant for neonatal vaccinations, rapidly enhancing protective humoral responses when combined with Pnc1‐TT.</jats:p> |
|---|---|
| Umfang: | 194-202 |
| ISSN: |
0300-9475
1365-3083 |
| DOI: | 10.1111/j.1365-3083.2008.02225.x |